Men's News
OncoLink Cancer Resource Home

OncoLink Cancer Resource Home

Men's News

OncoLink Cancer Resource Home
Types of Cancer Home
OncoLink Cancer Resource
Cancer Treatment Information Physician List
OncoLink Cancer Resource
Coping with Cancer MCC Staff
OncoLink Cancer Resource
Cancer Clinical Trials Matching Service Provider News
OncoLink Cancer Resource
Cancer Resources and News Women's News
OncoLink Cancer Resource
Ask the Cancer Experts Men's News
OncoLink Cancer Resource
OncoLink Cancer Library Treatment Protocols
OncoLink Cancer Resource
Cancer and Oncology Sponsors Cancer Control Protocols
OncoLink Cancer Resource
Giving to Oncolink's Cancer Resources Radiation Oncology
About Oncolink's Cancer Resources Upcoming Protocols
Giving to Oncolink's Cancer Resources Closed Protocols
Giving to Oncolink's Cancer Resources Related Links
Oncolink Cancer Resource Home


[SELECT logo]


  Press Release-SELECT Results Publication

         Important Study Update

                 Press Release

  Montana Cancer Consortium is participating in the National Cancer Institute cancer prevention trial - SELECT.  More than 35,000 men are participating in SELECT from the United States, Canada, and Puerto Rico.  This 12-year study is trying to determine if taking selenium and/or vitamin E can prevent prostate and other cancers.  These volunteers have helped to set a new pace for recruitment to clinical trials.  This largest-ever prostate cancer prevention trial began enrollment in August, 2001.  It was expected to take 5 years to recruit the 32,400 men needed to complete the study.  SELECT recruitment exceeded this total in less than 3 years.

 click here for: SELECT   SWOG website                              MEN FIGHTING TO PREVENT PROSTATE CANCER

Click Here for the National Institutes of Health website on Prostate Cancer (click "next page" 4 times for link to SELECT video)

Click Here for prostate cancer information


List of SELECT Publications

The SELECT Data and Safety Monitoring Committee (DSMC) met in September 2008 to review the data to date. Thanks to each and every participant, enough data were available to make a decision about the effectiveness of the Study Supplements. The data showed that 200 mg of selenium and 400 IUs daily of vitamin E do not prevent prostate cancer. Investigators from the study leadership and the National Cancer Institute agreed with the DSMCís findings. Participants in SELECT should stop taking their Study Supplements.   

SELECT is not over. There is valuable information to be gained by continuing participant follow-up. The data to date suggest, but do not prove, that vitamin E may slightly increase the chance of getting prostate cancer, and that selenium may increase the chance of getting diabetes mellitus. We emphasize that these findings are not proven. We will learn more about the effects of the Study Supplements as we continue to monitor our participantsí health. Participant safety is our priority.

The study site staff will gather information on participantsí current health and medical information at study site visits. As one of the largest medical studies of men, SELECT will help answer many critical questions about menís health and will assist scientists in the future.

Participants will receive a letter about this transition from the study leadership. The letter will be mailed to them by their local study site. Continue to check this website for periodic updates. If you are a participant in SELECT, you can contact your Study Site for more information. Contact information for your Study Site can be found in the list of SELECT Study Sites.

Thanks to all the participants on SELECT, we now know that selenium and vitamin E do not prevent prostate cancer. This important public health message is a result of over 35,000 men participating in SELECT. The SELECT National Participant Advisory Board and the leadership of SELECT appreciate each participantís commitment. The best way for participants to maximize their contribution is to continue to participate in SELECT.

Frequently Asked Questions and Responses

1. Why did SELECT get these results, when previous studies suggested that selenium and vitamin E are helpful?

Answer: The incidence, or rate of occurrence, of prostate cancer in the other studies was not the primary focus or endpoint. Men in those studies were not screened with the blood test of PSA (prostate specific antigen) and DRE (digital rectal exam) regularly. SELECT is the only study where the question of whether either selenium or vitamin E would prevent prostate cancer was asked directly and where prostate cancer was the primary endpoint.

2. Should you avoid taking a multivitamin that contains either or both of these supplements?

Answer: No, as long as you take only one multivitamin a day.

3. Since vitamin E and selenium donít work, is there anything else you can do to help reduce your risk of prostate cancer?

Answer: The Prostate Cancer Prevention Trial (PCPT) showed that taking the drug finasteride reduces the risk of prostate cancer by 25%. You should discuss with your doctor whether it makes sense for you to take finasteride. Finasteride may also be prescribed for men with lower urinary tract symptoms due to prostate enlargement (BPH).

4. Why do we still want to collect data from SELECT participants if we already know the results?

Answer: These supplements, selenium and vitamin E, may have biologic effects even after you stop taking them. We want to continue to collect data to learn of any long-term effects of these supplements on the risk of prostate cancer and other diseases including cardiovascular disease and other cancers.

5. Is there any value or harm if you eat foods high in selenium or vitamin E?

Answer: There are no proven benefits or harms if you eat foods high in selenium or vitamin E.

What is SELECT?
The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a research study to determine if selenium and vitamin E can help prevent prostate cancer. SELECT is funded by the National Cancer Institute and coordinated by the Southwest Oncology Group. Over 35,000 men, from a variety of ethnic groups, including 14% African American, 5% Hispanic, 1% Hispanic African American, and 1% Asian, from over 400 Study Sites in the United States, Puerto Rico, and Canada are participating in SELECT.

Want more information about prostate cancer?
To find out more about prostate cancer risk factors, prevention, screening, diagnosis, treatment, or clinical trials, please click on the links provided or contact the National Cancer Institute's Cancer Information Service at 1-800-4-Cancer (1-800-422-6237) or TTY: 1-800-332-8615. In Canada, call the Canadian Cancer Societyís Cancer Information Service at 1-888-939-3333.






Updated 8/15/2013

No Safe Cigarette

Prostate Cancer Prevention

Prostate Cancer Treatment

Prostate Cancer Risks

Other Helpful Websites



Confused by Prostate Cancer Treatment Options

There is little good research directly comparing prostate cancer treatment options to help the newly diagnosed choose between surgery, two types of radiation, or watching a small tumor to see if it needs treating at all.  Two new studies suggest the advice gap has consequences:  over-treating early-stage tumors, and therapy choices driven by fear and misconceptions. 

Not all prostate cancer is the same.  Certainly aggressive prostate cancer can kill, but often, prostate cancer is so slow-growing, and discovered when it's so small, that men will die of something else before it ever causes symptoms, much less becomes life-threatening.    One man in every six will get prostate cancer, but only one in 34 will die of it, according to the American Cancer Society.   That sounds reassuring until you're the man wondering if you'll be in the lucky majority or not.  Unfortunately, doctors have no easy way to tell.

Many studies are contradictory and there are no newer studies comparing the more modern surgical and radiation techniques.  So doctors typically just present all the options and let men choose.

If you are faced with making a decision about your treatment for prostate cancer, click on the website link above for comparisons of the various treatments and scientific data available.

Michigan Cancer Consortium /Washington (AP)

OncoLink Cancer Resource Home